文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

宿主反应检测SeptiCyte LAB在ICU中鉴别脓毒症与全身炎症反应综合征的验证

Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01
一句话结论在成人重症患者中,SeptiCyte LAB鉴别脓毒症与非感染性全身炎症的AUC为0.82–0.89,评分越高脓毒症相对可能性越大,且不受年龄、性别、种族影响。

本研究为前瞻性、观察性、非干预性设计,纳入美国7个中心成人重症患者249例,另加荷兰MARS consortium trial招募的198例,共447例。以三名专家回顾性医师诊断为标准,评估SeptiCyte LAB鉴别脓毒症与非感染性全身炎症的性能。ROC曲线分析显示AUC为0.82–0.89;脓毒症相对于非感染性全身炎症的似然比随测试评分(范围0–10)升高而增加。前向logistic回归显示,该检测联合其他临床和实验室变量(包括降钙素原)仅边际改善诊断性能;年龄、性别、种族/民族等人口学变量对性能无显著影响。结论认为SeptiCyte LAB似乎是有前景的诊断工具,可辅助医师评估全身炎症成人重症患者的感染可能性。

要点

  • 在447例成人重症患者中,SeptiCyte LAB鉴别脓毒症与非感染性全身炎症的ROC曲线AUC为0.82–0.89。
  • 测试评分范围0–10,脓毒症相对于非感染性全身炎症的似然比随评分升高而增加。
  • 该检测联合其他临床和实验室变量(包括降钙素原)时诊断性能仅边际改善。
  • 年龄、性别、种族/民族等人口学变量对该检测性能无显著影响。
  • 作者认为SeptiCyte LAB似乎是有前景的诊断工具,可辅助医师评估全身炎症成人重症患者的感染可能性。

适用人群与场景

  • 美国7个中心招募的成人重症患者249例,为异质性队列。
  • 荷兰MARS consortium trial招募的198例患者,共447例。

研究设计与关键结果

  • 研究为前瞻性、观察性、非干预性设计,共纳入447例成人重症患者(美国7个中心249例,荷兰MARS trial 198例)。
  • 以三名专家回顾性医师诊断为标准,SeptiCyte LAB鉴别脓毒症与非感染性全身炎症的ROC曲线AUC为0.82–0.89。
  • 脓毒症相对于非感染性全身炎症的似然比随测试评分(范围0–10)升高而增加。
  • 前向logistic回归分析显示,该检测联合其他临床和实验室变量(包括降钙素原)时诊断性能仅边际改善。
  • 年龄、性别、种族/民族等人口学变量对检测性能无显著影响。

证据类型、等级与局限

  • 证据类型:前瞻性、观察性、非干预性诊断性能研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为SeptiCyte LAB似乎是有前景的诊断工具,可辅助医师评估全身炎症成人重症患者的感染可能性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: A molecular test to distinguish between sepsis and systemic inflammation of noninfectious etiology could potentially have clinical utility.

OBJECTIVES: This study evaluated the diagnostic performance of a molecular host response assay (SeptiCyte LAB) designed to distinguish between sepsis and noninfectious systemic inflammation in critically ill adults.

METHODS: The study employed a prospective, observational, noninterventional design and recruited a heterogeneous cohort of adult critical care patients from seven sites in the United States (n = 249). An additional group of 198 patients, recruited in the large MARS (Molecular Diagnosis and Risk Stratification of Sepsis) consortium trial in the Netherlands ( www.clinicaltrials.gov identifier NCT01905033), was also tested and analyzed, making a grand total of 447 patients in our study. The performance of SeptiCyte LAB was compared with retrospective physician diagnosis by a panel of three experts.

MEASUREMENTS AND MAIN RESULTS: In receiver operating characteristic curve analysis, SeptiCyte LAB had an estimated area under the curve of 0.82-0.89 for discriminating sepsis from noninfectious systemic inflammation. The relative likelihood of sepsis versus noninfectious systemic inflammation was found to increase with increasing test score (range, 0-10). In a forward logistic regression analysis, the diagnostic performance of the assay was improved only marginally when used in combination with other clinical and laboratory variables, including procalcitonin. The performance of the assay was not significantly affected by demographic variables, including age, sex, or race/ethnicity.

CONCLUSIONS: SeptiCyte LAB appears to be a promising diagnostic tool to complement physician assessment of infection likelihood in critically ill adult patients with systemic inflammation. Clinical trial registered with www.clinicaltrials.gov (NCT01905033 and NCT02127502).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Miller RR, Lopansri BK, Burke JP, et al. Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. Am J Respir Crit Care Med. 2018. PMID: 29624409. doi:10.1164/rccm.201712-2472OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。